Zusammenfassung
Die Prognose lokal fortgeschrittener Magen- und Ösophaguskarzinome ist ungünstig. Durch multimodale Behandlungsstrategien lässt sich die Prognose im Vergleich zu alleiniger chirurgischer Therapie verbessern. Zwei in Europa durchgeführte randomisierte Studien zeigten, dass die perioperative Chemotherapie zu einem signifikanten Überlebensvorteil für Patienten mit Magenkarzinomen und Adenokarzinomen des gastroösophagealen Übergangs führt. Die Ergebnisse haben einen nachhaltigen Einfluss auf die aktuelle Therapie dieser Tumoren in den klinischen Stadien II und III. Aufgrund aktueller Metanalysen werden Patienten mit lokal fortgeschrittenen Adenokarzinomen des Ösophagus entweder mit Chemotherapie oder mit Radiochemotherapie vorbehandelt. Plattenepithelkarzinome des Ösophagus werden mittels kombinierter Radiochemotherapie behandelt. Die nachfolgende Resektion ist optional. Patienten mit lokal fortgeschrittenen Magen- und Ösophaguskarzinomen sollten immer in einem onkologischen Zentrum vorgestellt werden, wo die Befunde im interdisziplinären Tumorboard besprochen werden. Die Prognose ist nachweislich besser, wenn die Therapie an ausgewiesenen Zentren erfolgt.
Abstract
The prognosis of locally advanced gastric and oesophageal cancers is poor, but it has been shown that multimodal treatment can lead to better outcomes than surgery alone. Two randomised studies conducted in Europe have shown that perioperative chemotherapy does significantly improve the survival of patients with adenocarcinoma of the stomach and oesophagogastric junction. These results have had a profound effect on the treatment of patients presenting with stage II or stage III disease. Because of the results of recent meta-analyses, patients with locally advanced adenocarcinomas of the oesophagus receive neoadjuvant chemotherapy or chemoradiation therapy. Squamous cell cancer of the oesophagus is treated with chemoradiation. Secondary resection is optional. Patients with locally advanced gastric and oesophageal cancer should always be referred to an experienced high-volume centre where findings are discussed by a multidisciplinary tumour board. It has been demonstrated that outcomes are better when such patients are treated in designated centres.
Literatur
Bedenne L, Michel P, Bouché O et al (2005) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25: 1160–1168
Boige V, Pignon JP, Saint-Aubert B et al (2007) Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 25 (Suppl 18S): 4510 (abstract)
Cascinu S, Labianca R, Barone C et al (2007) Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 99: 601–607
Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11–20
D’Angelica M, Gonen M, Brennan MF et al (2004) Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 240: 808–816
Gebski V, Burmeister B, Smithers BM et al (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226–234
Fiorica F, Cartei F, Enea M et al (2007) The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat Rev 33: 729–740
Fiorica F, Di Bona D, Schepis F et al (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53: 925–930
Glockzin G, Ghali N, Lang SA et al (2007) Peritoneal carcinomatosis: Surgical treatment, including hyperthermal intraperitoneal chemotherapy. Chirurg 78: 1100–1110
Janunger KG, Hafstrom L, Glimelius B (2002) Chemotherapy in gastric cancer: a review und updated meta-analysis. Eur J Surg 168: 597–608
Kelsen DP, Winter KA, Gunderson LL et al (2007) Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25: 3719–3725
Lordick F (2005) Neoadjuvant therapy for squamous cell carcinoma of the esophagus. Chirurg 76: 1025–1032
Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8: 797–805
Lordick F, Ott K, Novotny A et al (2007) R1 resection in the surgery of upper gastrointestinal tumors: Relevance and therapeutic consequences. Chirurg 78: 792–801
Lordick F, Ott K, Weitz J, Jäger D (2008) The evolving role of catumaxomab in gastric cancer. Expert Opin Biol Ther 8: 1407–1415
Lordick F, Ruers T, Aust DE et al (2008) European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer 44: 1807–1819
Lordick F, Stein HJ, Peschel C, Siewert JR (2004) Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 91: 540–551
Lorenzen S, Hentrich M, Haberl C et al (2007) Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 18: 1673–1679
Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725–730
Rosen HR, Jatzko G, Repse S et al (1998) Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 16: 2733–2738
Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810–1820
Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23: 2310–2317
Stahl M, Walz MK, Stuschke M et al (2007) Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy (CRTX) in locally advanced esophagogastric adenocarcinomas: First results of a randomized phase III trial. J Clin Oncol 25 (Suppl 18S): 4511 (abstract)
Steyerberg EW, Neville BA, Koppert LB et al (2006) Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 24: 4277–4284
Tachimori Y, Kanamori N, Uemura N et al (2009) Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 137: 49–54
Van Cutsem E, Van de Velde C, Roth A et al (2008) Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group. Eur J Cancer 44: 182–194
Witzig R, Schönberger B, Fink U et al (2006) Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma. Endoscopy 38: 1122–1126
Yan TD, Black D, Sugarbaker PH et al (2007) A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 14: 2702–2713
Zhao SL, Fang JY (2008) The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest 26: 317–325
Interessenskonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lordick, F., Ott, K. Neoadjuvante und adjuvante Therapie des Magen- und Ösophaguskarzinoms. Gastroenterologe 4, 224–231 (2009). https://doi.org/10.1007/s11377-008-0272-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11377-008-0272-0